Home Hepatitis Liver biopsy findings in patients on immune checkpoint inhibitors

Liver biopsy findings in patients on immune checkpoint inhibitors

Credits to the Source Link Daniel
Liver biopsy findings in patients on immune checkpoint inhibitors
  • 1.

    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    CAS 
    Article 

    Google Scholar
     

  • 2.

    Kurashima Y, Kiyono H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu Rev Immunol. 2017;35:119–47.

    CAS 
    Article 

    Google Scholar
     

  • 3.

    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–55.

    CAS 
    Article 

    Google Scholar
     

  • 4.

    Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.

    CAS 
    Article 

    Google Scholar
     

  • 5.

    Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol. 2018;9:180.

    Article 

    Google Scholar
     

  • 6.

    Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv264–iv266.

    CAS 
    Article 

    Google Scholar
     

  • 7.

    Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124:3706–14.

    CAS 
    Article 

    Google Scholar
     

  • 8.

    Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol. 2019;40:511–23.

    CAS 
    Article 

    Google Scholar
     

  • 9.

    Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36:2872–8.

    CAS 
    Article 

    Google Scholar
     

  • 10.

    Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, et al. Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases. Am J Surgical Pathol. 2015;39:1075–84.

    Article 

    Google Scholar
     

  • 11.

    Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J surgical Pathol. 2017;41:134–7.

    Article 

    Google Scholar
     

  • 12.

    Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965–73.

    Article 

    Google Scholar
     

  • 13.

    Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh MM. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology. 2020;76:470–80.

    Article 

    Google Scholar
     

  • 14.

    Hamoir C, de Vos M, Clinckart F, Nicaise G, Komuta M, Lanthier N. Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy. J Gastroenterol Hepatol. 2018;33:1695.

    CAS 
    Article 

    Google Scholar
     

  • 15.

    Kono M, Sakurai T, Okamoto K, Masaki S, Nagai T, Komeda Y, et al. Efficacy and safety of chemotherapy following Anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis. Intern Med. 2019;58:1263–6.

    Article 

    Google Scholar
     

  • 16.

    Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs. 2018;36:144–6.

    Article 

    Google Scholar
     

  • 17.

    Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest N. Drugs. 2017;35:529–36.

    CAS 
    Article 

    Google Scholar
     

  • 18.

    Kuraoka N, Hara K, Terai S, Yatabe Y, Horio Y. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. Endoscopy. 2018;50:E259–E261.

    Article 

    Google Scholar
     

  • 19.

    Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol. 2017;28:671–2.

    CAS 
    Article 

    Google Scholar
     

  • 20.

    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

    Article 

    Google Scholar
     

  • 21.

    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.

    CAS 
    Article 

    Google Scholar
     

  • 22.

    Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61–65.

    Article 

    Google Scholar
     

  • 23.

    Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017;2:e000268.

    Article 

    Google Scholar
     

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: